NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
34 trialsNCT04008238 2026-03-06
PIPER
Institut Bergonié
Phase NA Completed
NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04794127 2026-02-18
TRABEPIO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05597917 2025-04-04
TRABTRAP
Universität Münster
Phase 3 Recruiting
NCT06524583 2025-03-30
L-UteCIN
UNICANCER
Phase 2 Recruiting
NCT03164980 2025-03-20
COMPASS
North Eastern German Society of Gynaecological Oncology
Phase 4 Terminated
NCT03138161 2025-02-24
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 1/2 Recruiting
NCT03886311 2025-02-24
TNT
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT03127215 2024-05-08
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
Phase 2 Completed
NCT03884972 2023-09-25
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02275286 2023-05-31
TRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Recruiting
NCT03985722 2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Unknown
NCT05131386 2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Unknown
NCT02359474 2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03590210 2022-11-08
NiTraSarc
University Medicine Greifswald
Phase 2 Completed
NCT03074318 2022-04-29
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT02194231 2020-01-23
ATREUS
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01735071 2019-11-19
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT03496519 2018-10-09
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
Phase 1 Withdrawn
NCT02672527 2018-08-16
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT02249702 2017-12-06
TAUL
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01104298 2015-10-27
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Terminated
NCT01426633 2014-12-16
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Heidelberg University
Phase 1 Completed
NCT01339754 2014-08-11
PACT-18
IRCCS San Raffaele
Phase 2 Completed
NCT00005625 2013-06-19
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01772979 2013-01-21
MITO15
Catholic University of the Sacred Heart
Phase 2 Unknown
NCT00147212 2013-01-18
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed